文献速递肿瘤 PET/CT神经核医学

无创89Zr-转铁蛋白PET在MYC过表达人三阴性乳腺癌中显示较18F-FDG PET更优的肿瘤靶向性

Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer.
PubMed 文献 · J Nucl Med · 2017-08-28

该研究在三阴性乳腺癌(TNBC)临床前模型中头对头比较89Zr-转铁蛋白与18F-FDG PET,发现89Zr-转铁蛋白对TNBC肿瘤的靶向性显著优于18F-FDG(P<0.05-0.001)。BRD4抑制剂JQ1和OTX015处理可降低c-Myc与TfR基因及蛋白表达,并减少转铁蛋白受体介导的内化。

要点

  • 在MDA-MB-231、MDA-MB-157移植瘤及患者来源移植瘤模型中,89Zr-转铁蛋白靶向TNBC肿瘤显著优于18F-FDG(P<0.05-0.001)。
  • BRD4抑制剂JQ1和OTX015(0.5-1 μM)处理可降低响应细胞系的c-Myc与TfR基因表达(P<0.01-0.001)。
  • 药物处理后在MDA-MB-231和MDA-MB-157细胞中MYC与TfR蛋白表达及转铁蛋白受体内化也显著降低(P<0.01-0.001)。

核心结论

  • 89Zr-转铁蛋白通过PET显像和生物分布研究显示,对人TNBC原发肿瘤的靶向性显著优于18F-FDG。
  • 89Zr-转铁蛋白是通过TfR靶向PET显像探究TNBC中MYC状态的有用工具。

研究设计与样本

  • 在TNBC临床前模型中头对头比较89Zr-转铁蛋白与18F-FDG PET显像及生物分布。
  • 使用TNBC细胞MDA-MB-157、MDA-MB-231和Hs578T,以BRD4抑制剂JQ1和OTX015(0.5-1 μM)处理。
  • 检测细胞增殖、基因表达和蛋白表达,以探究抑制剂对MYC和TfR的影响。
  • 在MDA-MB-231和MDA-MB-157移植瘤及TNBC患者来源移植瘤模型中进行显像与生物分布研究。

主要发现

  • 头对头比较显示,在MDA-MB-231和MDA-MB-157移植瘤及TNBC患者来源移植瘤模型中,89Zr-转铁蛋白靶向TNBC肿瘤显著优于18F-FDG(P<0.05-0.001)。
  • 与溶媒处理相比,BRD4抑制剂及c-MYC小干扰RNA处理使响应细胞系的c-Myc和TfR基因表达降低(P<0.01-0.001)。
  • 药物处理使MDA-MB-231和MDA-MB-157细胞中MYC和TfR蛋白表达及受体介导的转铁蛋白内化显著降低(P<0.01-0.001)。

关键数值与推荐

  • BRD4抑制剂JQ1和OTX015的使用浓度为0.5-1 μM。
  • 89Zr-转铁蛋白对比18F-FDG的靶向优势P值范围为P<0.05-0.001。
  • 基因表达降低的P值范围为P<0.01-0.001(响应细胞系)。
  • 蛋白表达及内化降低的P值范围为P<0.01-0.001(MDA-MB-231和MDA-MB-157细胞)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The current standard for breast PET imaging is 18F-FDG. The heterogeneity of 18F-FDG uptake in breast cancer limits its utility, varying greatly among receptor status, histopathologic subtypes, and proliferation markers. 18F-FDG PET often exhibits nonspecific internalization and low specificity and sensitivity, especially with tumors smaller than 1 cm3 MYC is a protein involved in oncogenesis and is overexpressed in triple-negative breast cancer (TNBC). Increased surface expression of transferrin receptor (TfR) is a downstream event of MYC upregulation and has been validated as a clinically relevant target for molecular imaging. Transferrin labeled with 89Zr has successfully identified MYC status in many cancer subtypes preclinically and been shown to predict response and changes in oncogene status via treatment with small-molecule inhibitors that target MYC and PI3K signaling pathways. We hypothesized that 89Zr-transferrin PET will noninvasively detect MYC and TfR and improve upon the current standard of 18F-FDG PET for MYC-overexpressing TNBC. Methods: In this study, 89Zr-transferrin and 18F-FDG imaging were compared in preclinical models of TNBC. TNBC cells (MDA-MB-157, MDA-MB-231, and Hs578T) were treated with bromodomain-containing protein 4 (BRD4) inhibitors JQ1 and OTX015 (0.5-1 μM). Cell proliferation, gene expression, and protein expression were assayed to explore the effects of these inhibitors on MYC and TfR. Results: Head-to-head comparison showed that 89Zr-transferrin targets TNBC tumors significantly better (P < 0.05-0.001) than 18F-FDG through PET imaging and biodistribution studies in MDA-MB-231 and MDA-MB-157 xenografts and a patient-derived xenograft model of TNBC. c-Myc and TfR gene expression was decreased upon treatment with BRD4 inhibitors and c-MYC small interfering RNA (P < 0.01-0.001 for responding cell lines), compared with vehicle treatment. MYC and TfR protein expression, along with receptor-mediated internalization of transferrin, was also significantly decreased upon drug treatment in MDA-MB-231 and MDA-MB-157 cells (P < 0.01-0.001). Conclusion:89Zr-transferrin targets human TNBC primary tumors significantly better than 18F-FDG, as shown through PET imaging and biodistribution studies. 89Zr-transferrin is a useful tool to interrogate MYC via TfR-targeted PET imaging in TNBC.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Henry KE, Dilling TR, Abdel-Atti D, et al. Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. J Nucl Med. 2017. PMID: 28848040. doi:10.2967/jnumed.117.192286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。